company background image
0HNC logo

BioMarin Pharmaceutical LSE:0HNC Stock Report

Last Price

US$65.93

Market Cap

US$12.6b

7D

-1.9%

1Y

-31.5%

Updated

24 Dec, 2024

Data

Company Financials +

BioMarin Pharmaceutical Inc.

LSE:0HNC Stock Report

Market Cap: US$12.6b

0HNC Stock Overview

Engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. More details

0HNC fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance5/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 68.8% below our estimate of its fair value

Earnings are forecast to grow 27.91% per year

Earnings grew by 119.2% over the past year

Risk Analysis

0HNC passed our risk checks.

My Notes

Capture your thoughts, links and company narrative

BioMarin Pharmaceutical Inc. Competitors

Genus

LSE:GNS

UK£1.0b

Bioventix

AIM:BVXP

UK£167.0m

Hikma Pharmaceuticals

LSE:HIK

UK£4.4b

GSK

LSE:GSK

UK£54.7b

Price History & Performance

Summary of share price highs, lows and changes for BioMarin Pharmaceutical
Historical stock prices
Current Share PriceUS$65.93
52 Week HighUS$98.79
52 Week LowUS$61.15
Beta0.29
1 Month Change2.49%
3 Month Change-4.30%
1 Year Change-31.52%
3 Year Change-26.47%
5 Year Change-22.60%
Change since IPO-28.02%

Recent News & Updates

Recent updates

Shareholder Returns

0HNCGB BiotechsGB Market
7D-1.9%-5.0%-1.9%
1Y-31.5%-24.4%2.6%

Return vs Industry: 0HNC underperformed the UK Biotechs industry which returned -24.4% over the past year.

Return vs Market: 0HNC underperformed the UK Market which returned 2.6% over the past year.

Price Volatility

Is 0HNC's price volatile compared to industry and market?
0HNC volatility
0HNC Average Weekly Movement3.2%
Biotechs Industry Average Movement6.9%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.7%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0HNC has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0HNC's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19963,401Alexander Hardywww.biomarin.com

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.

BioMarin Pharmaceutical Inc. Fundamentals Summary

How do BioMarin Pharmaceutical's earnings and revenue compare to its market cap?
0HNC fundamental statistics
Market capUS$12.63b
Earnings (TTM)US$322.29m
Revenue (TTM)US$2.75b

39.2x

P/E Ratio

4.6x

P/S Ratio

Is 0HNC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0HNC income statement (TTM)
RevenueUS$2.75b
Cost of RevenueUS$1.31b
Gross ProfitUS$1.44b
Other ExpensesUS$1.12b
EarningsUS$322.29m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.69
Gross Margin52.35%
Net Profit Margin11.71%
Debt/Equity Ratio11.0%

How did 0HNC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 18:01
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioMarin Pharmaceutical Inc. is covered by 56 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Ishan MajumdarBaptista Research
Huidong WangBarclays